SPECIAL NOTICE
66 -- ThyroSeq Genomic Classifier Test (Brand Name ONLY)
- Notice Date
- 12/6/2023 8:21:09 AM
- Notice Type
- Special Notice
- NAICS
- 621511
— Medical Laboratories
- Contracting Office
- 246-NETWORK CONTRACTING OFFICE 6 (36C246) HAMPTON VA 23667 USA
- ZIP Code
- 23667
- Solicitation Number
- 36C24624Q0129
- Response Due
- 12/8/2023 1:30:00 PM
- Archive Date
- 01/07/2024
- Point of Contact
- Chellry Whittier, Contract Specialist, Phone: 757-728-7125
- E-Mail Address
-
chellry.whittier@va.gov
(chellry.whittier@va.gov)
- Awardee
- null
- Description
- NOTICE OF INTENT TO AWARD SOLE-SOURCE The Department of Veteran Affairs, Veterans Health Administration, Network Contracting Office 6, Hampton VA 23667, intends to negotiate a sole source Firm-Fixed Price contract for the upgrade and installation of the ThyroSeq Genomic Classifier Testing (brand name ONLY) for the Fayetteville, Asheville, and Durham VA Medical Centers with Cytopath Biopsy Lab, Inc. dba CBLPath, Inc. in accordance with 41 U.S.C. ยง3304(a)(1) as implemented by FAR 6.302-1 Only One Responsible Source. This purchase will be made under Simplified Acquisition Procedures and Other than Full and Open Competition as authorized by FAR 13.106-1(b). This is not a request for competitive offers, and no solicitation is available. Market research has determined that these items are highly specialized and are only available from a single source without an unacceptable delay or duplication of cost. No other type of items will satisfy agency requirements. The Government intends to award the contract with an effective date of December 15, 2023, to CBLPath, Inc.; 760 Westchester Avenue, Rye Brook, NY 10573-1341, SAM UEI: KC5VWAGMNLT6. The Fayetteville, Asheville, and Durham VA Medical Centers requires the molecular testing of thyroid nodules with a base year plus one on contract. Molecular testing of thyroid nodule fine-needle aspiration (FNA) specimens has been found to assist in the assessment of indeterminate thyroid nodules. Molecular testing can detect genetic alterations associated with thyroid malignancy. Molecular testing of an indeterminate thyroid nodule can stratify patients into those who may or may not need a surgical procedure. This synopsis announcement is being issued for information purposes only and does not constitute a solicitation or request for competitive proposals. If a firm believes it is capable of meeting the Government's requirement, it may identify its interest and capability to the contract specialist within three (3) business days of this publication by contacting Chellry Whittier via e-mail at chellry.whittier@va.gov. Telephone inquiries will not be accepted. This announcement closes on December 08, 2023, at 4:30 PM EDT. Those interested firms must indicate whether they are large, small, small disadvantaged, 8(a) or woman-owned businesses and whether they are U.S. or foreign-owned. Respondents who submit proprietary data shall clearly mark the data with appropriate markings. The Government will not pay for any information submitted as a result of this synopsis. This synopsis shall not be construed as an obligation on the part of the Government to acquire any products or services. ***Reference RFQ 36C24624Q0129 in all replies***
- Web Link
-
SAM.gov Permalink
(https://sam.gov/opp/35bd0b7af6e04a1a802e0b9a8672e45a/view)
- Record
- SN06903969-F 20231208/231206230044 (samdaily.us)
- Source
-
SAM.gov Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's SAM Daily Index Page |